Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

INTRODUCTION: Parkinson’s disease (PD) is a common neurodegenerative disorder with substantial morbidity. No disease-modifying treatments currently exist. The glucagon like peptide-1 receptor agonist exenatide has been associated in single-centre studies with reduced motor deterioration over 1 year....

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMJ Open
Main Authors: Vijiaratnam, Nirosen, Girges, Christine, Auld, Grace, Chau, Marisa, Maclagan, Kate, King, Alexa, Skene, Simon, Chowdhury, Kashfia, Hibbert, Steve, Morris, Huw, Limousin, Patricia, Athauda, Dilan, Carroll, Camille B, Hu, Michele T, Silverdale, Monty, Duncan, Gordon W, Chaudhuri, Ray, Lo, Christine, Del Din, Silvia, Yarnall, Alison J, Rochester, Lynn, Gibson, Rachel, Dickson, John, Hunter, Rachael, Libri, Vincenzo, Foltynie, Thomas
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2021
Assuntos:
Neurology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8166598/
https://ncbi.nlm.nih.gov/pubmed/34049922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-047993
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares